CD276 and glioma: Recognizing the clinical limitations of ZOL and BTN3A1 agonistic antibody in glioma, especially given the high B7H3 expression in the majority of GBM cases, we genetically engineered Vγ9Vδ2 T cells into Car-B7H3-γδT cells.